Cancer registries
czech english

Please note: Data collection for the registry has been terminated.

The CORECT registry is a non-interventional post-registration database focused on collection of epidemiological and clinical data of patients with colorectal carcinoma (CRC) treated with bevacizumab, cetuximab, and panitumumab. The project was initiated in July 2011 by the Czech Society for Oncology. Obtained data allow for monitoring of CRC patients' treatment and its results. Institute of Biostatistics and Analyses Ltd, a spin-off company of the Masaryk University, provides management and other services to this project.

Primary goals

  • Documentation of treatment of patients with CRC treated with targeted agents

Secondary goals

  • Assessment of treatment effectiveness in routine clinical practice (each line separately)
    • Overall survival defined as time between therapy initiation and patient's death
    • Progression-free survival defined as time between therapy initiation and disease progression or death
    • Patient's response to treatment according to RECIST criteria
  • Evaluation of safety of the targeted therapy in clinical practice
  • Epidemiological description of the patients cohort and the disease


In association with increasing number of the targeted therapies approved for treatment of metastatic CRC, several clinical registries have been developed, which were focused on treatment with individual targeted agents for this indication. Board of the Czech Society for Oncology at the CzMA therefore agreed to solve this situation by development of a new registry, which would integrate data collected within the frame of previous projects. Thus, the CORECT registry has currently served for monitoring of treatment by three targeted agents together - bevacizumab (Avastin), cetuximab (Erbitux), and panitumumab (Vectibix). In case of approval of further drugs for the treatment of CRC, these will be easily included in the registry structure.

Witin the frame of the original registries integration, previously collected data were transferred into the new CORECT registry structure. The integration has removed necessity to enter data on particular patient's treatment into different registries, which allows for obtaining comprehensive and transparent information about overall treatment of the patient, monitoring of therapy sequences and patient's response to the treatment.

The project will undoubtedly increase quality and effectiveness of data collection and simplify work of registry users. Besides of patients' epidemiological characteristics, it will also allow for modelling of risk factors for patients' survival and analysis of adverse effects. The registry may also serve for economical purposes and estimations, such as planning of costs for anticancer treatment.